Merck
  • Início
  • Resultados da busca
  • An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival.

An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival.

Oncotarget (2014-07-06)
Antoine M Snijders, Sasha Langley, Jian-Hua Mao, Sandhya Bhatnagar, Kathleen A Bjornstad, Chris J Rosen, Alvin Lo, Yurong Huang, Eleanor A Blakely, Gary H Karpen, Mina J Bissell, Andrew J Wyrobek
RESUMO

The concept that a breast cancer patient's menstrual stage at the time of tumor surgery influences risk of metastases remains controversial. The scarcity of comprehensive molecular studies of menstrual stage-dependent fluctuations in the breast provides little insight in this observation. To gain a deeper understanding of the biological changes in mammary tissue and blood during the menstrual cycle and to determine the influence of environmental exposures, such as low-dose ionizing radiation (LDIR), we used the mouse to characterize estrous-cycle variations in mammary gene transcripts by RNA-sequencing, peripheral white blood cell (WBC) counts and plasma cytokine levels. We identified an estrous-variable and hormone-dependent gene cluster enriched for Type-1 interferon genes. Cox regression identified a 117-gene signature of interferon-associated genes, which correlated with lower frequencies of metastasis in breast cancer patients. LDIR (10cGy) exposure had no detectable effect on mammary transcripts. However, peripheral WBC counts varied across the estrous cycle and LDIR exposure reduced lymphocyte counts and cytokine levels in tumor-susceptible mice. Our finding of variations in mammary Type-1 interferon and immune functions across the estrous cycle provides a mechanism by which timing of breast tumor surgery during the menstrual cycle may have clinical relevance to a patient's risk for distant metastases.

MATERIAIS
Número do produto
Marca
Descrição do produto

Supelco
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
Progesterone, European Pharmacopoeia (EP) Reference Standard
Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard
Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Progesterone, γ-irradiated, BioXtra, suitable for cell culture
Supelco
Progesterone, VETRANAL®, analytical standard
Sigma-Aldrich
β-Estradiol, ≥98%
Sigma-Aldrich
Progesterone, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Progesterone, meets USP testing specifications
Sigma-Aldrich
Progesterone, ≥99%
Sigma-Aldrich
Uracil, BioReagent, suitable for cell culture
Sigma-Aldrich
Uracil, ≥99.0%
Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard
Supelco
Uracil, Pharmaceutical Secondary Standard; Certified Reference Material